Literature DB >> 11253131

Downregulation of transforming growth factor beta type II receptor in laryngeal carcinogenesis.

A Franchi1, O Gallo, I Sardi, M Santucci.   

Abstract

AIMS: To investigate whether anomalies of transforming growth factor beta type II receptor (TGF-beta RII) expression occur in the early stages of laryngeal carcinogenesis and to assess their importance in the development of laryngeal squamous cell carcinoma. TGF-beta RII status was examined in laryngeal premalignant lesions coupled with malignant evolution and compared with a control group of similar lesions without progression to cancer.
METHODS: Immunohistochemical staining for TGF-beta RII was performed on 15 paraffin wax embedded biopsies from patients with precancerous laryngeal lesions who subsequently developed invasive squamous cell carcinoma of the larynx, and on 30 control biopsies from patients who did not develop cancer in a comparable follow up period. In addition, DNA extracted from 18 preneoplastic lesions and eight squamous cell carcinomas was amplified by the polymerase chain reaction at the poly A and the poly GT regions of the TGF-beta RII gene.
RESULTS: In the group of lesions with progression to carcinoma, 11 of 15 cases showed loss (< 20% of epithelial cells) of TGF-beta RII immunoreactivity, whereas among non-evolved lesions only five of 30 had similar altered expression of the receptor (p < 0.001, two tailed Fisher's exact test). All squamous cell carcinomas showed a degree of receptor expression comparable with that of the corresponding preneoplastic lesion, with the exception of one case, in which loss of the receptor was evident only in invasive cancer. Mutation of the poly A sequence of the TGF-beta RII gene was identified in only one precancerous lesion and in the subsequent squamous cell carcinoma.
CONCLUSIONS: These findings indicate that the downregulation of TGF-beta RII is an early event in laryngeal carcinogenesis, which may result in the loss of TGF-beta mediated growth inhibition, thereby facilitating the progression of laryngeal precancerous lesions to squamous cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11253131      PMCID: PMC1731366          DOI: 10.1136/jcp.54.3.201

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  26 in total

1.  Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I: An inventory in search of autocrine and paracrine loops.

Authors:  J S de Jong; P J van Diest; P van der Valk; J P Baak
Journal:  J Pathol       Date:  1998-01       Impact factor: 7.996

2.  Frequent aberration of the transforming growth factor-beta receptor II gene in cell lines but no apparent mutation in pre-invasive and invasive carcinomas of the uterine cervix.

Authors:  T Y Chu; J S Lai; C Y Shen; H S Liu; C F Chao
Journal:  Int J Cancer       Date:  1999-02-09       Impact factor: 7.396

3.  Regulation of growth and differentiation of human keratinocytes by type beta transforming growth factor and epidermal growth factor.

Authors:  M Reiss; A C Sartorelli
Journal:  Cancer Res       Date:  1987-12-15       Impact factor: 12.701

4.  Selective inhibition of growth-related gene expression in murine keratinocytes by transforming growth factor beta.

Authors:  R J Coffey; C C Bascom; N J Sipes; R Graves-Deal; B E Weissman; H L Moses
Journal:  Mol Cell Biol       Date:  1988-08       Impact factor: 4.272

5.  Expression of transforming growth factor beta type II receptors in head and neck squamous cell carcinoma.

Authors:  C A Muro-Cacho; M Anderson; J Cordero; T Muñoz-Antonia
Journal:  Clin Cancer Res       Date:  1999-06       Impact factor: 12.531

6.  Gene mutation of transforming growth factor beta1 type II receptor in hepatocellular carcinoma.

Authors:  K Furuta; S Misao; K Takahashi; T Tagaya; Y Fukuzawa; T Ishikawa; K Yoshioka; S Kakumu
Journal:  Int J Cancer       Date:  1999-06-11       Impact factor: 7.396

7.  High frequency of resistance of human squamous carcinoma cells to the anti-proliferative action of transforming growth factor beta.

Authors:  M Reiss; E B Stash
Journal:  Cancer Commun       Date:  1990

8.  Mutation and downregulation of the transforming growth factor beta type II receptor gene in primary squamous cell carcinomas of the head and neck.

Authors:  D Wang; H Song; J A Evans; J C Lang; D E Schuller; C M Weghorst
Journal:  Carcinogenesis       Date:  1997-11       Impact factor: 4.944

9.  Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas.

Authors:  M Goggins; M Shekher; K Turnacioglu; C J Yeo; R H Hruban; S E Kern
Journal:  Cancer Res       Date:  1998-12-01       Impact factor: 12.701

Review 10.  Retinoid chemoprevention of aerodigestive cancer: from basic research to the clinic.

Authors:  W Ki Hong; S M Lippman; W N Hittelman; R Lotan
Journal:  Clin Cancer Res       Date:  1995-07       Impact factor: 12.531

View more
  3 in total

Review 1.  Biomarkers predicting malignant progression of laryngeal epithelial precursor lesions: a systematic review.

Authors:  Juan P Rodrigo; Juana María García-Pedrero; Carlos Suárez; Robert P Takes; Lester D R Thompson; Pieter J Slootweg; Julia A Woolgar; William H Westra; Ruud H Brakenhoff; Alessandra Rinaldo; Kenneth O Devaney; Michelle D Williams; Douglas R Gnepp; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-11-12       Impact factor: 2.503

Review 2.  Current understanding of the tumor microenvironment of laryngeal dysplasia and progression to invasive cancer.

Authors:  Sumita Trivedi; Clark A Rosen; Robert L Ferris
Journal:  Curr Opin Otolaryngol Head Neck Surg       Date:  2016-04       Impact factor: 2.064

3.  Esophageal squamous cell carcinoma invasion is inhibited by Activin A in ACVRIB-positive cells.

Authors:  Holli A Loomans; Shanna A Arnold; Laura L Quast; Claudia D Andl
Journal:  BMC Cancer       Date:  2016-11-09       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.